Skip to main content

Cordex Systems welcomes Nobel Laureate Dr. Louis J. Ignarro to its Scientific Advisory Board

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Cordex Systems, Inc. announces that Dr. Louis J. Ignarro, 1998 Nobel Laureate in Physiology or Medicine, has joined its Scientific Advisory Board to advance nitric oxide-based cardiovascular diagnostic technology.

-- Cordex Systems, Inc. announced that Dr. Louis J. Ignarro, Nobel Laureate in Physiology or Medicine, has joined the company's Scientific Advisory Board.

Dr. Ignarro received the 1998 Nobel Prize in Physiology or Medicine for his landmark discovery that nitric oxide (NO) functions as a critical signaling molecule in the cardiovascular system — research that fundamentally transformed the understanding of vascular biology and opened a new chapter in cardiovascular medicine. Heart disease is the number one killer of men and women in the world, killing more people than all cancers combined, and in the past 30 years more than 170,000 studies have been published on endothelial function in both human and animal models. Valentin Fuster, MD, PhD, president of Mount Sinai Fuster Heart Hospital and Physician-in-Chief of The Mount Sinai Hospital, said at the time: "The discovery of nitric oxide and its function is one of the most important in the history of cardiovascular medicine." (The New York Times, Oct. 13, 1998.)

Dr. Ignarro's expertise is directly relevant to the science powering the Cordex Smart Cuff. The device takes a direct, calibrated measurement of endothelial function by quantifying vascular compliance — the effect of nitric oxide on arterial stiffness. Endothelial dysfunction, driven by diminished nitric oxide production or bioavailability, is an independent predictor of major adverse cardiac events (MACE), including heart attack, stroke and heart failure. By measuring this biological pathway non-invasively at the point of care, Cordex is translating Dr. Ignarro's foundational science into actionable clinical intelligence.

"Having the scientist who discovered nitric oxide's role in the cardiovascular system advising Cordex is both a profound validation and an extraordinary opportunity. Dr. Ignarro's work is the scientific foundation upon which our technology is built," said Kathy Magliato, MD, Founder, Chief Executive Officer and Chief Medical Officer of Cordex Systems, Inc.

"Nitric oxide's role in vascular health is something I've studied for decades, and it's exciting to see that science translated into a practical tool clinicians can use at the point of care. I look forward to supporting Cordex as they bring endothelial function measurement into everyday cardiovascular care," said Dr. Louis J. Ignarro.

Dr. Ignarro is Professor Emeritus of Molecular and Medical Pharmacology at the UCLA School of Medicine, a member of the National Academy of Sciences, and a recipient of the American Heart Association Distinguished Scientist Award, among numerous other honors spanning more than four decades of research.

About Cordex Systems

Cordex Systems, Inc. is a privately held medical device company developing innovative solutions to address heart disease - the number one killer of men and women in the world. The company has designed, patented, and clinically tested its flagship Smart Cuff™ in more than 700 patients. The Smart Cuff provides a direct, calibrated, non-invasive measurement of endothelial function at the point of care, grounded in Nobel Prize-winning nitric oxide science. Endothelial function is a critical metric in maintaining optimal cardiovascular health. For more information, visit cordexsystems.com.

Media contact

Simone Giacometti Cordex Systems, Inc. simone@cordexsystems.com www.cordexsystems.com

Contact Info:
Name: Simone Giacometti
Email: Send Email
Organization: Cordex Systems
Website: https://cordexsystems.com

Release ID: 89197952

Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.96
+7.47 (3.02%)
AAPL  327.50
+12.64 (4.01%)
AMD  529.14
-18.99 (-3.46%)
BAC  61.59
+0.97 (1.60%)
GOOG  370.21
+12.88 (3.60%)
META  681.31
+20.27 (3.07%)
MSFT  395.63
+10.70 (2.78%)
NVDA  212.50
+0.70 (0.33%)
ORCL  132.49
+4.55 (3.56%)
TSLA  394.46
-1.72 (-0.43%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.